Both TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Editas Medicine Inc. (NASDAQ:EDIT) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TRACON Pharmaceuticals Inc.	3.00M	14.75	34.96M	-1.47	0.00
Editas Medicine Inc.	31.94M	37.82	109.95M	-2.67	0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of TRACON Pharmaceuticals Inc. and Editas Medicine Inc.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both companies.

	Net Margins	Return on Equity	Return on Assets
TRACON Pharmaceuticals Inc.	-1,165.33%	-75.2%	-46.2%
Editas Medicine Inc.	-344.24%	-58.1%	-34%

Liquidity

The Current Ratio of TRACON Pharmaceuticals Inc. is 3.6 while its Quick Ratio stands at 3.6. The Current Ratio of rival Editas Medicine Inc. is 13.1 and its Quick Ratio is has 13.1. Editas Medicine Inc. is better equipped to clear short and long-term obligations than TRACON Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both TRACON Pharmaceuticals Inc. and Editas Medicine Inc. are owned by institutional investors at 65.7% and 78.7% respectively. 0.4% are TRACON Pharmaceuticals Inc.’s share held by insiders. Competitively, 2.5% are Editas Medicine Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
TRACON Pharmaceuticals Inc.	20.56%	51.76%	16.22%	-38.57%	-47.35%	104.76%
Editas Medicine Inc.	13.81%	9.62%	-18.9%	-24.93%	-32.52%	4.7%

For the past year TRACON Pharmaceuticals Inc. was more bullish than Editas Medicine Inc.

Summary

Editas Medicine Inc. beats TRACON Pharmaceuticals Inc. on 7 of the 10 factors.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.